Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group
Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydr...
Gespeichert in:
| Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 1997-07, Vol.30 (1 Pt 1), p.140-145 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 1 Pt 1 |
| container_start_page | 140 |
| container_title | Hypertension (Dallas, Tex. 1979) |
| container_volume | 30 |
| creator | Reisin, E Weir, M R Falkner, B Hutchinson, H G Anzalone, D A Tuck, M L |
| description | Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (-8.3 and -7.7 versus -3.3 mm Hg, respectively; P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79146000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79146000</sourcerecordid><originalsourceid>FETCH-LOGICAL-p534-83d53b3d9e272c849cea1a6bb5f5a798f5e641faa670fe52d10754c3de021dc73</originalsourceid><addsrcrecordid>eNo9kM1KxDAYRbtQxnH0EYSsRBeVpEn_3MmgM8LADFpQVyVNvtJI2tQkHRifyke0anF1udzDWdyjYI5JzsKckNeT4NS5d4wJYyydBbM8oiSjbB58bZRTnemt0mgP1g0ONQdpjWi0scY3in8qCUh1yFTgYBx7sB46p_aAeu4VdN7dIo7aQXslxgYW9ZoLqEwoTOet0Rok8lZxfYMKC9y3I_Vj3P4ad5MEvSjfoPW_33Toqnja7tZv1-jZD_KAVtYM_VlwXHPt4HzKRVA83BfLdbjZrh6Xd5uwjykLMypjWlGZQ5RGImO5AE54UlVxHfM0z-oYEkZqzpMU1xBHkuA0ZoJKwBGRIqWL4PJP21vzMYDzZaucAK15B2ZwZZoTlmCMR_BiAoeqBVmOT7bcHsrpYfoNwe97tQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79146000</pqid></control><display><type>article</type><title>Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Reisin, E ; Weir, M R ; Falkner, B ; Hutchinson, H G ; Anzalone, D A ; Tuck, M L</creator><creatorcontrib>Reisin, E ; Weir, M R ; Falkner, B ; Hutchinson, H G ; Anzalone, D A ; Tuck, M L</creatorcontrib><description><![CDATA[Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (-8.3 and -7.7 versus -3.3 mm Hg, respectively; P<.005) and systolic (-9.2 and -10.0 versus -4.6 mm Hg, respectively; P<.05) pressures compared with placebo. Ambulatory blood pressure monitoring confirmed that lisinopril and hydrochlorothiazide effectively lowered 24-hour blood pressure compared with placebo (P<.001). Significant dose-response differences were observed between treatments. Sixty percent of patients treated with lisinopril had an office diastolic pressure <90 mm Hg compared with 43% of patients treated with hydrochlorothiazide (P<.05). Responses to therapies differed with both race and age. Neither treatment significantly affected insulin or lipid profiles; however, plasma glucose increased significantly after 12 weeks of hydrochlorothiazide therapy compared with lisinopril (+0.31 versus -0.21 mmol/L; P<.001). Hydrochlorothiazide also decreased serum potassium levels by 0.4 mmol/L from baseline. In conclusion, lisinopril was as effective as hydrochlorothiazide in treating obese patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors may show greater efficacy as monotherapy at lower doses compared with thiazide diuretics, may have a more rapid rate of response, and may offer advantages in patients at high risk of metabolic disorders.]]></description><identifier>ISSN: 0194-911X</identifier><identifier>PMID: 9231834</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - therapeutic use ; Blood Pressure Monitors ; Body Mass Index ; Data Interpretation, Statistical ; Diuretics ; Female ; Humans ; Hydrochlorothiazide - administration & dosage ; Hydrochlorothiazide - therapeutic use ; Hypertension - drug therapy ; Lisinopril - administration & dosage ; Lisinopril - therapeutic use ; Male ; Middle Aged ; Obesity - complications ; Sodium Chloride Symporter Inhibitors - administration & dosage ; Sodium Chloride Symporter Inhibitors - therapeutic use ; Time Factors</subject><ispartof>Hypertension (Dallas, Tex. 1979), 1997-07, Vol.30 (1 Pt 1), p.140-145</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9231834$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reisin, E</creatorcontrib><creatorcontrib>Weir, M R</creatorcontrib><creatorcontrib>Falkner, B</creatorcontrib><creatorcontrib>Hutchinson, H G</creatorcontrib><creatorcontrib>Anzalone, D A</creatorcontrib><creatorcontrib>Tuck, M L</creatorcontrib><title>Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description><![CDATA[Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (-8.3 and -7.7 versus -3.3 mm Hg, respectively; P<.005) and systolic (-9.2 and -10.0 versus -4.6 mm Hg, respectively; P<.05) pressures compared with placebo. Ambulatory blood pressure monitoring confirmed that lisinopril and hydrochlorothiazide effectively lowered 24-hour blood pressure compared with placebo (P<.001). Significant dose-response differences were observed between treatments. Sixty percent of patients treated with lisinopril had an office diastolic pressure <90 mm Hg compared with 43% of patients treated with hydrochlorothiazide (P<.05). Responses to therapies differed with both race and age. Neither treatment significantly affected insulin or lipid profiles; however, plasma glucose increased significantly after 12 weeks of hydrochlorothiazide therapy compared with lisinopril (+0.31 versus -0.21 mmol/L; P<.001). Hydrochlorothiazide also decreased serum potassium levels by 0.4 mmol/L from baseline. In conclusion, lisinopril was as effective as hydrochlorothiazide in treating obese patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors may show greater efficacy as monotherapy at lower doses compared with thiazide diuretics, may have a more rapid rate of response, and may offer advantages in patients at high risk of metabolic disorders.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Blood Pressure Monitors</subject><subject>Body Mass Index</subject><subject>Data Interpretation, Statistical</subject><subject>Diuretics</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrochlorothiazide - administration & dosage</subject><subject>Hydrochlorothiazide - therapeutic use</subject><subject>Hypertension - drug therapy</subject><subject>Lisinopril - administration & dosage</subject><subject>Lisinopril - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - complications</subject><subject>Sodium Chloride Symporter Inhibitors - administration & dosage</subject><subject>Sodium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Time Factors</subject><issn>0194-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1KxDAYRbtQxnH0EYSsRBeVpEn_3MmgM8LADFpQVyVNvtJI2tQkHRifyke0anF1udzDWdyjYI5JzsKckNeT4NS5d4wJYyydBbM8oiSjbB58bZRTnemt0mgP1g0ONQdpjWi0scY3in8qCUh1yFTgYBx7sB46p_aAeu4VdN7dIo7aQXslxgYW9ZoLqEwoTOet0Rok8lZxfYMKC9y3I_Vj3P4ad5MEvSjfoPW_33Toqnja7tZv1-jZD_KAVtYM_VlwXHPt4HzKRVA83BfLdbjZrh6Xd5uwjykLMypjWlGZQ5RGImO5AE54UlVxHfM0z-oYEkZqzpMU1xBHkuA0ZoJKwBGRIqWL4PJP21vzMYDzZaucAK15B2ZwZZoTlmCMR_BiAoeqBVmOT7bcHsrpYfoNwe97tQ</recordid><startdate>199707</startdate><enddate>199707</enddate><creator>Reisin, E</creator><creator>Weir, M R</creator><creator>Falkner, B</creator><creator>Hutchinson, H G</creator><creator>Anzalone, D A</creator><creator>Tuck, M L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199707</creationdate><title>Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group</title><author>Reisin, E ; Weir, M R ; Falkner, B ; Hutchinson, H G ; Anzalone, D A ; Tuck, M L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p534-83d53b3d9e272c849cea1a6bb5f5a798f5e641faa670fe52d10754c3de021dc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Blood Pressure Monitors</topic><topic>Body Mass Index</topic><topic>Data Interpretation, Statistical</topic><topic>Diuretics</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrochlorothiazide - administration & dosage</topic><topic>Hydrochlorothiazide - therapeutic use</topic><topic>Hypertension - drug therapy</topic><topic>Lisinopril - administration & dosage</topic><topic>Lisinopril - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - complications</topic><topic>Sodium Chloride Symporter Inhibitors - administration & dosage</topic><topic>Sodium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reisin, E</creatorcontrib><creatorcontrib>Weir, M R</creatorcontrib><creatorcontrib>Falkner, B</creatorcontrib><creatorcontrib>Hutchinson, H G</creatorcontrib><creatorcontrib>Anzalone, D A</creatorcontrib><creatorcontrib>Tuck, M L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reisin, E</au><au>Weir, M R</au><au>Falkner, B</au><au>Hutchinson, H G</au><au>Anzalone, D A</au><au>Tuck, M L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>1997-07</date><risdate>1997</risdate><volume>30</volume><issue>1 Pt 1</issue><spage>140</spage><epage>145</epage><pages>140-145</pages><issn>0194-911X</issn><abstract><![CDATA[Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (-8.3 and -7.7 versus -3.3 mm Hg, respectively; P<.005) and systolic (-9.2 and -10.0 versus -4.6 mm Hg, respectively; P<.05) pressures compared with placebo. Ambulatory blood pressure monitoring confirmed that lisinopril and hydrochlorothiazide effectively lowered 24-hour blood pressure compared with placebo (P<.001). Significant dose-response differences were observed between treatments. Sixty percent of patients treated with lisinopril had an office diastolic pressure <90 mm Hg compared with 43% of patients treated with hydrochlorothiazide (P<.05). Responses to therapies differed with both race and age. Neither treatment significantly affected insulin or lipid profiles; however, plasma glucose increased significantly after 12 weeks of hydrochlorothiazide therapy compared with lisinopril (+0.31 versus -0.21 mmol/L; P<.001). Hydrochlorothiazide also decreased serum potassium levels by 0.4 mmol/L from baseline. In conclusion, lisinopril was as effective as hydrochlorothiazide in treating obese patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors may show greater efficacy as monotherapy at lower doses compared with thiazide diuretics, may have a more rapid rate of response, and may offer advantages in patients at high risk of metabolic disorders.]]></abstract><cop>United States</cop><pmid>9231834</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-911X |
| ispartof | Hypertension (Dallas, Tex. 1979), 1997-07, Vol.30 (1 Pt 1), p.140-145 |
| issn | 0194-911X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79146000 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adult Aged Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use Blood Pressure Monitors Body Mass Index Data Interpretation, Statistical Diuretics Female Humans Hydrochlorothiazide - administration & dosage Hydrochlorothiazide - therapeutic use Hypertension - drug therapy Lisinopril - administration & dosage Lisinopril - therapeutic use Male Middle Aged Obesity - complications Sodium Chloride Symporter Inhibitors - administration & dosage Sodium Chloride Symporter Inhibitors - therapeutic use Time Factors |
| title | Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lisinopril%20versus%20hydrochlorothiazide%20in%20obese%20hypertensive%20patients:%20a%20multicenter%20placebo-controlled%20trial.%20Treatment%20in%20Obese%20Patients%20With%20Hypertension%20(TROPHY)%20Study%20Group&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Reisin,%20E&rft.date=1997-07&rft.volume=30&rft.issue=1%20Pt%201&rft.spage=140&rft.epage=145&rft.pages=140-145&rft.issn=0194-911X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E79146000%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79146000&rft_id=info:pmid/9231834&rfr_iscdi=true |